Media stories about Immunomedics (NASDAQ:IMMU) have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Immunomedics earned a news impact score of 0.10 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.9875380560653 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

Shares of Immunomedics (IMMU) opened at $12.44 on Monday. The company has a current ratio of 0.74, a quick ratio of 0.74 and a debt-to-equity ratio of -0.29. Immunomedics has a 1 year low of $3.30 and a 1 year high of $14.48.

A number of research analysts have weighed in on the stock. BidaskClub raised shares of Immunomedics from a “hold” rating to a “buy” rating in a research note on Wednesday, August 23rd. ValuEngine lowered shares of Immunomedics from a “hold” rating to a “sell” rating in a research note on Monday, December 4th. Zacks Investment Research raised shares of Immunomedics from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research note on Wednesday, October 4th. Finally, Jefferies Group set a $11.00 price target on shares of Immunomedics and gave the company a “buy” rating in a research note on Thursday, August 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $15.33.

In other Immunomedics news, Director Venbio Select Advisor Llc acquired 1,150,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were acquired at an average price of $10.39 per share, with a total value of $11,948,500.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Brian A. Markison sold 8,390 shares of the business’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $11.89, for a total transaction of $99,757.10. Following the completion of the sale, the director now directly owns 99,178 shares in the company, valued at approximately $1,179,226.42. The disclosure for this sale can be found here. Insiders own 6.60% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Immunomedics (IMMU) Earning Somewhat Favorable Press Coverage, Accern Reports” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/11/immunomedics-immu-earning-somewhat-favorable-press-coverage-accern-reports.html.

Immunomedics Company Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Insider Buying and Selling by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Stock Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related stocks with our FREE daily email newsletter.